A multicenter retrospective study investigating the safety and efficacy of immune checkpoint inhibitors in lung cancer with interstitial pneumonia

A multicenter retrospective study investigating the safety and efficacy of immune checkpoint inhibitors in lung cancer with interstitial pneumonia - A multicenter retrospective study investigating the safety and efficacy of immune checkpoint inhibitors in lung cancer with interstitial pneumonia

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043974

Enrollment

200

Registered

2021-04-20

Start date

2021-04-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer with interstitial pneumonia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed with primary lung cancer 2) Patients with interstitial pneumonia 3) Patients who received immune checkpoint inhibitors

Exclusion criteria

Exclusion criteria: 1) Radiation pneumonia 2) Drug-induced pneumonia 3) Interstitial lung abnormality

Design outcomes

Primary

Measure	Time frame
Frequency of drug-induced lung injury as an immune-related adverse event and rate of serious adverse events in patients treated with immune checkpoint inhibitors for primary lung cancer with interstitial pneumonia	—

Secondary

Measure	Time frame
1) Response rate of immune checkpoint inhibitors 2) Progression-free survival 3) Overall survival 4) Duration of treatment	—

Countries

Japan

Contacts

Public ContactKazutoshi Isobe

Toho University School of Medicine Division of Respiratory Medicine

kazutoshiisobe@med.toho-u.ac.jp03-3762-4151

Outcome results